The company is also entering new markets, such as neuromodulation for treatment-resistant depression, a $1 billion opportunity. Overall, Abbott’s innovation and broad product portfolio position ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

Abbott cautions that these forward-looking ... a meaningful growth driver for our vascular business. And lastly, in Neuromodulation, we began treating patients in our TRANSCEND clinical trial ...

Abbott Laboratories (NYSE ... this to become a meaningful growth driver for our vascular business. And lastly, neuromodulation. We began treating patients in our TRANSCEND clinical trial, a ...

Boston has established a significant footprint in CRM, stents, electrophysiology, endoscopy, urology, neuromodulation ... Medtronic, and Abbott hold more than 90% of the global CRM market ...

Boston has established a significant footprint in CRM, stents, electrophysiology, endoscopy, urology, neuromodulation ... Medtronic, and Abbott hold more than 90% of the global CRM market ...